Comparison of Standard and Extended Dexamethasone Duration on Mortality in Patients with Severe COVID-19
Division
West Florida
Hospital
Citrus Memorial Hospital
Document Type
Manuscript
Publication Date
12-1-2024
Keywords
Humans, Dexamethasone, Female, Male, Retrospective Studies, Hospital Mortality, COVID-19 Drug Treatment, COVID-19, Aged, Middle Aged, SARS-CoV-2, Respiration, Artificial, Drug Administration Schedule, Glucocorticoids
Disciplines
Cardiology | Internal Medicine | Medicine and Health Sciences | Pulmonology | Respiratory Tract Diseases | Virus Diseases
Abstract
OBJECTIVES: Current guidelines recommend dexamethasone 6 mg/day for up to 10 days in patients with severe coronavirus disease 2019 (COVID-19) requiring supplemental oxygenation or mechanical ventilation. The practice has significant variation, however, and dexamethasone has been used for >10 days for many patients with severe COVID-19. The aim of this study was to assess the benefits and risks associated with standard versus extended use of dexamethasone in patients with severe COVID-19.
METHODS: A multicenter retrospective cohort study was conducted from January 2021 to December 2021. All of the consecutive patients with severe COVID-19 receiving 6 mg/day dexamethasone were eligible for inclusion. The primary outcome was the incidence of in-hospital mortality for patients treated with dexamethasone 6 mg/day for the standard duration of 10 days versus an extended duration of >10 days.
RESULTS: A total of 1294 patients met the inclusion criteria: 803 received the standard duration of dexamethasone and 491 received the extended duration. The incidence of in-hospital mortality was significantly higher (
CONCLUSIONS: The results show that extended duration of dexamethasone compared with standard duration is associated with a significant increase in in-hospital mortality in patients with severe COVID-19. These findings need to be confirmed in well-designed and performed randomized controlled trials.
Publisher or Conference
Southern Medical Journal
Recommended Citation
Sephien A, Lozano M, Prince SP, et al. Comparison of Standard and Extended Dexamethasone Duration on Mortality in Patients with Severe COVID-19. South Med J. 2024;117(12):701-704. doi:10.14423/SMJ.0000000000001760